Overview

A Phase 1, First-in-human Study of VX-828

Status:
Recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate safety, tolerability, and pharmacokinetics of VX-828 in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Treatments:
Itraconazole
Midazolam